We performed a retrospective observational study to examine the incidence of invasive aspergillosis (IA) among allogeneic hematopoietic stem cell transplant (HSCT) recipients, according to whether patients received at least 1 week of voriconazole prophylaxis. We report no cases of IA among 92 HSCT recipients who received voriconazole prophylaxis compared with a 10% (23/223) incidence among those receiving other systemic antifungals for prophylaxis (P < .0005).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diagmicrobio.2006.01.018DOI Listing

Publication Analysis

Top Keywords

voriconazole prophylaxis
12
incidence invasive
8
invasive aspergillosis
8
aspergillosis allogeneic
8
allogeneic hematopoietic
8
hematopoietic stem
8
stem cell
8
cell transplant
8
hsct recipients
8
transplant patients
4

Similar Publications

Uncommon concurrent pulmonary infections: and in an Anti-MDA5 antibody-positive dermatomyositis patient.

Med Mycol Case Rep

March 2025

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

A 59-year-old female with anti-MDA5 antibody-positive dermatomyositis was treated with prednisolone, tacrolimus, cyclophosphamide, tofacitinib, and plasma exchange. Five months post-treatment, elevated β-D-glucan levels and a pulmonary shadow on CT were noted. was identified, leading to voriconazole initiation.

View Article and Find Full Text PDF

The impact of , , and polymorphisms on tacrolimus dose-adjusted concentration and clinical outcomes in adult allogeneic hematopoietic stem cell transplantation.

Xenobiotica

January 2025

Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215123, China.

1. Polymorphisms in genes related to drug-metabolizing genes may affect tacrolimus exposure. This study aimed to assess the influence of , , and polymorphisms on tacrolimus pharmacokinetics and outcomes in allogeneic hematopoietic stem cell transplantation (HSCT).

View Article and Find Full Text PDF

While the majority of spp. isolated in clinical laboratories are typically associated with episodes of colonization or superficial infections, this fungal species has gained recognition as an opportunistic pathogen, leading to invasive infections worldwide. In this article, we present a case series of spp.

View Article and Find Full Text PDF

Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0).

Clin Infect Dis

December 2024

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Article Synopsis
  • This study assessed the occurrence of invasive fungal disease (IFD) in patients who received allogeneic stem cell transplants in China during 2021.
  • A total of 2015 patients were involved, with 76% receiving mold-active antifungal prophylaxis, yet the cumulative incidence of IFD was found to be 6.3% within a year post-transplant.
  • Key risk factors for IFD included advanced disease stages, delayed engraftment of neutrophils and platelets, and severe graft-versus-host disease, contributing to an IFD-related mortality rate of 48.28%.
View Article and Find Full Text PDF

We report a case of a 15-year-old with refractory and relapsed AML and profound prolonged neutropenia who developed a disseminated invasive infection while on echinocandin prophylaxis for invasive fungal disease. Azole antifungal therapies, which are often used as prophylaxis, were initially avoided due to concerns for CYP drug interactions. Treatment with a combination of liposomal amphotericin B, voriconazole, and adjuvant granulocyte transfusions was successful as he awaited neutrophil recovery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!